Trial Profile
A Double-Blind, Placebo-Controlled Study of a Combination Product (BCI-024 and BCI-049) in Patients With Major Depressive Disorder (MDD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Buspirone/melatonin (Primary) ; Buspirone
- Indications Major depressive disorder
- Focus Therapeutic Use
- 30 Apr 2010 Results reported in a BrainCells media release.
- 27 Jul 2009 Results have been presented at NCDEU 2009, according to a BrainCells Inc media release.
- 29 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.